Welcome to our dedicated page for Q32 BIO news (Ticker: QTTB), a resource for investors and traders seeking the latest updates and insights on Q32 BIO stock.
Q32 Bio Inc. (QTTB) is a clinical stage biotechnology company whose public updates focus on the development of bempikibart (ADX-914) and related immune-targeted programs. The company regularly issues news releases on its progress in alopecia areata (AA) and other autoimmune and inflammatory diseases, providing detail on clinical trial milestones, regulatory interactions, and corporate developments.
Much of Q32 Bio’s recent news centers on the SIGNAL-AA Phase 2a clinical trial of bempikibart in severe and very severe alopecia areata. Press releases describe key events such as dosing of the first patients in Part B and the open-label extension, completion of enrollment in Part B, emerging signs of clinical activity, and plans for topline data readouts. The company also reports on presentations of SIGNAL-AA data at major medical meetings, including a late-breaking oral presentation at the American Academy of Dermatology Annual Meeting.
Investors following QTTB news can also see announcements about regulatory designations, such as the U.S. Food and Drug Administration’s Fast Track designation for bempikibart in alopecia areata, and corporate transactions, including the sale of the complement inhibitor ADX-097 to Akebia Therapeutics, Inc. Financial result releases provide updates on cash and cash equivalents, research and development spending, and the company’s stated expectations for its financial runway in relation to clinical milestones.
This QTTB news page aggregates these company-issued updates, including SEC-related press releases furnished on Form 8-K, clinical development progress reports, leadership changes such as the appointment of an interim Chief Medical Officer, and participation in healthcare conferences. Readers can use this feed to monitor how Q32 Bio describes the evolution of its bempikibart program, its complement platform strategy, and its overall clinical and corporate trajectory.
Q32 Bio (Nasdaq: QTTB) has priced an underwritten public offering of 6,027,399 shares of common stock at $18.25 per share and pre-funded warrants for 4,931,506 shares at $18.2499 per warrant, each warrant carrying a $0.0001 per share exercise price. The company also granted underwriters a 30-day option to buy up to 1,643,835 additional common shares at the public offering price, less underwriting discounts and commissions.
Gross proceeds are expected to be about $200 million, before fees and expenses, assuming no exercise of the underwriters’ option and excluding any warrant exercises. The offering, with all securities sold by Q32 Bio, is expected to close on or about July 16, 2026, subject to customary conditions. According to Q32 Bio, net proceeds will support working capital, research, clinical development and commercialization efforts, including advancing bempikibart into future clinical trials. The securities are being issued under an effective Form S-3 shelf registration statement declared effective on July 13, 2026.
Q32 Bio (Nasdaq: QTTB) has commenced an underwritten public offering of $200 million of common stock and, for certain investors, pre-funded warrants to purchase common shares. The company expects to grant underwriters a 30-day option to buy up to an additional $30 million of common stock at the public offering price, less underwriting discounts and commissions. All securities in the proposed offering will be sold by Q32 Bio.
Morgan Stanley, Jefferies and Cantor are joint book-running managers, with Oppenheimer as additional book-runner and H.C. Wainwright as lead manager. Q32 Bio plans to use net proceeds for working capital, including research, clinical development, commercialization and advancement of bempikibart into future trials. The offering is being made under an effective shelf registration statement on Form S-3, remains subject to market and other conditions, and may not be completed as currently proposed.
Q32 Bio (Nasdaq: QTTB) reported positive 36-week topline data from Part B of the Phase 2a SIGNAL-AA trial of bempikibart in 33 patients with severe or very severe alopecia areata. The prespecified primary endpoint showed a mean 35.3% reduction in SALT score from baseline in the mITT population.
At Week 36, 40.0% (10/25) of mITT patients and 30.3% (10/33) of ITT patients achieved a SALT-20 response, while 44.0% of mITT and 33.3% of ITT patients reached SALT30 and SALT50 responses. Early off-drug durability signals included maintenance or deepening of response and one patient achieving complete hair regrowth (SALT = 0). Bempikibart showed a generally well-tolerated safety profile with no treatment-related SAEs or Grade ≥3 events; injection site reactions occurred in 36.3% of patients and were mild. Pharmacokinetic and ADA data supported the loading-dose regimen, and Q32 Bio plans a registration-directed program in the first half of 2027.
Q32 Bio (Nasdaq: QTTB), a clinical-stage biotechnology company developing therapies for alopecia areata and other autoimmune and inflammatory diseases, will report 36-week topline results from Part B of the SIGNAL-AA Phase 2a trial of bempikibart in severe or very severe alopecia areata on Monday, July 13, 2026.
According to Q32 Bio, the company will host a live conference call and webcast with accompanying slides at 8:00 a.m. E.T. the same day to discuss the results. Investors can access the live or recorded webcast via the Investors section of the Q32 Bio website or join the live call by dialing 1-800-836-8184 in the United States or 1-646-357-8785 from other locations, or by logging into the provided webinar link.
Q32 Bio (NASDAQ:QTTB) entered a securities purchase agreement for a private placement of common stock and pre-funded warrants totaling approximately $55 million. The company will issue 6,725,000 shares at $8.00 and pre-funded warrants for 150,000 shares at $7.9999, led by BVF Partners, with closing expected May 28, 2026.
Q32 Bio (Nasdaq: QTTB) reported Q1 2026 results and operational updates on May 5, 2026. Key items: Part B of the SIGNAL-AA Phase 2a trial remains on-track with 36-week topline data expected mid-2026, first patient dosed in the Part B OLE, and Part A OLE complete. Q32 completed a $10.5M registered direct offering and reported $50.8M cash as of March 31, 2026, excluding $14.2M ATM proceeds received after quarter-end; company expects runway into 1H 2028 when combined with guaranteed milestone payments.
Q32 Bio (Nasdaq: QTTB) will participate in a fireside chat at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026 at 12:45 p.m. ET. A live webcast will be available on the company’s Events and Presentations page, with an archived replay accessible for 90 days.
Q32 Bio (Nasdaq: QTTB) reported Q4 2025 results and corporate updates. The company completed enrollment in Part B of SIGNAL-AA at 33 patients, expects 36-week topline data mid-2026, completed a $10.5M registered direct offering, and sold ADX-097 to Akebia with $12M near-term proceeds (including $7M received).
Cash was $48.3M at 12/31/2025; combined with RDO proceeds and ADX-097 payments, Q32 Bio expects runway into Q4 2027.
Q32 Bio (Nasdaq: QTTB) said management will appear in a fireside chat at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 2:00 p.m. ET.
A live webcast will be available on Q32 Bio's Events and Presentations page, with archived replays accessible for 90 days after the event.
Q32 Bio (NASDAQ: QTTB) announced a $10.5 million registered direct offering led by a new institutional investor, consisting of 1,666,679 common shares and pre-funded warrants to purchase up to 1,025,654 shares at $3.90 per share (pre-funded warrants priced at $3.8999).
Closing expected on or about February 18, 2026. Proceeds are intended to fund working capital and advance bempikibart into future clinical trials for alopecia areata.